BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
Covered in this story
What has happened since
- Vaxcyte Inc is down 9.6% since this was published.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
BTIG’s $89 target on $PCVX is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
BTIG’s track record →Call it yourself
No member calls on $PCVX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Vaxcyte Inc →Dalsna Finance is currently tracking 6 stories mentioning Vaxcyte Inc, the earliest published 5 Oct 2026.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.